Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] · 2025
Surgical Deroofing in the Management of Hidradenitis Suppurativa Alone or as an Adjunct to Medical Therapies.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Vu Trang T, Soong Laura C, Hagtvedt Reidar, Keeling Christopher P
Аннотация
BACKGROUND: Hidradenitis suppurativa (HS) is an inflammatory condition that remains challenging to manage. Deroofing is a surgical technique whereby the "dermal roof" of the entire lesion and sinus tracts are removed.
OBJECTIVE: A prospective study was conducted to assess the efficacy and safety of deroofing in the management of both acute and chronic HS lesions in Hurley Stage I-III disease. The role of deroofing as an adjunct to adalimumab and the impact of deroofing on pain control and quality of life (QoL) were also quantified.
METHODS: Forty-four patients were enrolled in an open, single arm study treated by a single clinician. In total, 115 lesions were deroofed and patients were followed at 3 and 12 months after deroofing.
RESULTS: At 3 and 12 months, the recurrence rate was 10% (12/115) and 11% (13/108), respectively. Deroofing is an effective adjunctive treatment for patients on adalimumab. Deroofing also improved pain and QoL scores.
CONCLUSION: Deroofing is a safe and effective surgical technique that can be used for acute and chronic recurrent/fixed lesions in Hurley I-III disease alone or as an adjunct to systemic therapies. Deroofing has a low recurrence rate, reduces pain, and improves QoL.
OBJECTIVE: A prospective study was conducted to assess the efficacy and safety of deroofing in the management of both acute and chronic HS lesions in Hurley Stage I-III disease. The role of deroofing as an adjunct to adalimumab and the impact of deroofing on pain control and quality of life (QoL) were also quantified.
METHODS: Forty-four patients were enrolled in an open, single arm study treated by a single clinician. In total, 115 lesions were deroofed and patients were followed at 3 and 12 months after deroofing.
RESULTS: At 3 and 12 months, the recurrence rate was 10% (12/115) and 11% (13/108), respectively. Deroofing is an effective adjunctive treatment for patients on adalimumab. Deroofing also improved pain and QoL scores.
CONCLUSION: Deroofing is a safe and effective surgical technique that can be used for acute and chronic recurrent/fixed lesions in Hurley I-III disease alone or as an adjunct to systemic therapies. Deroofing has a low recurrence rate, reduces pain, and improves QoL.